Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma
Mandate

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

November 03, 2016

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Related

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

 Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026

Vinge advises Stendörren in connection with issuance of subsequent green bonds

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of subsequent senior unsecured green bonds in an amount of SEK 300 million (within a framework of SEK 800 million).
February 18, 2026

Vinge advises DNB Carnegie in connection with a EUR 130 million bond issue to finance Incore Invest’s acquisition of CoreOrchestration

 Vinge has advised DNB Carnegie Investment Bank AB (publ), in its capacity as sole bookrunner, in connection with an issue of senior secured bonds of EUR 130 million under a framework of EUR 200 million.
February 16, 2026